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Aims: The pathophysiological roles of thyroid hormones in glucose metabolism remain uncertain. Type 3
iodothyronine deiodinase (D3) converts thyroxine (T4) and 3,5,3′-triiodothyronine (T3) to 3,3′,5′-triiodothyronine
(rT3) and 3,3′-diiodothyronine (T2), respectively, inactivating thyroid hormones in a cell-speciﬁc fashion. In the
present study, we identiﬁed D3 expression inMIN6 cells derived from amouse insulinoma cell line and examined
the mechanisms regulating D3 expression in these cells.
Mainmethods:WecharacterizedD3 activity usingHPLCanalysis, and examined the effect of GLP-1 or exendin-4 on
D3 expression and cAMP accumulation inMIN6 cells.We alsomeasured insulin secretion fromMIN6 cells exposed
to GLP-1 and T3.
Key ﬁndings:We identiﬁed enzyme activity that catalyzes the conversion of T3 to T2 in MIN6 cells, which showed
characteristics compatible with those for D3. D3 mRNA was identiﬁed in these cells using RT-PCR analysis.
Forskolin rapidly stimulated D3 mRNA and D3 activity. Glucagon-like peptide-1 (GLP-1) increased D3 expression
in a dose-dependent manner, and this effect was inhibited by the protein kinase A (PKA) inhibitor H-89. Exendin-
4, a GLP-1 receptor agonist, also stimulated D3 expression in MIN6 cells. These results suggest that a cAMP-PKA-
mediated pathway participates in GLP-1-stimulated D3 expression in MIN6 cells. Furthermore, GLP-1 stimulated
insulin secretion was suppressed by the addition of T3 in MIN6 cells.
Signiﬁcance: Our ﬁndings indicate that GLP-1 regulates intracellular T3 concentration in pancreatic β cells via a
cAMP-PKA-D3-mediated pathway that may also regulate β-cell function.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
The physiological roles of thyroid hormones in glucose homeostasis
remain debatable (Lenzen and Bailey, 1984; Chidakel et al., 2005). Sys-
temic hypothyroidism promotes fasting hyperglycemia and decreases
plasma insulin levels in mice following glucose stimulation (Taguchi
et al., 2010). 3,5,3′-Triiodothyronine (T3) enhances function and surviv-
al of rat pancreatic islets (Verga Falzacappa et al., 2010), and thyroid
hormone promotes postnatal rat pancreatic β-cell development and
glucose-responsive insulin secretion (Aguayo-Mazzucato et al., 2013).
Plasma free T3 concentrations are positively associated with insulin
secretion in euthyroid individuals (Ortega et al., 2008). Thyroid hor-
mone improves insulin resistance by acting on brown adipose tissue
(Skarulis et al., 2010) and modulates hepatic glucose production
(Klieverik et al., 2009). In contrast, systemic hyperthyroidism decreases
glucose tolerance and β-cell insulin secretory capacity (Lenzen et al.,Laboratory Medicine, Gunma
-machi, Maebashi, Gunma 371-
3.
kami).
. This is an open access article under1975; Ximenes et al., 2007). Reduced thyroid hormone signaling in
pancreatic β-cells is important for normal islet function and glucose ho-
meostasis (Medina et al., 2011). In rats, thyroxine (T4) is able to induce
apoptosis in pancreatic β-cells (Jörns et al., 2002). These observations
suggest that plasma thyroid hormone concentrations are related to
both insulin production and resistance.
T4, a major thyroid gland product, is converted to biologically active
T3 by iodothyronine deiodinase (Bianco et al., 2002). There are 3 types
of iodothyronine deiodinase: type 1 (D1), type 2 (D2), and type 3 (D3)
(Bianco et al., 2002). Both D1 and D2 remove iodine from the T4 outer
ring to form T3. D1 activity in rats is present in the thyroid, liver, kidney
andmany other tissues, and likely plays a role inmaintaining circulating
T3 levels (Bianco et al., 2002). D2 activity in rats is present in only a few
tissues, including the brain, anterior pituitary, and brown adipose tissue
(Bianco et al., 2002). Because D2 activity increases and D1 activity
decreases in the hypothyroid state, D2 plays a signiﬁcant role in provid-
ing intracellular T3 where it exists (Bianco et al., 2002). In contrast, D3
removes iodine from the T4 and T3 inner rings to form the inactive thy-
roid hormones 3,3′,5′-triiodothyronine (rT3) and 3,3′-diiodothyronine
(T2), respectively (Gereben et al., 2008). D3 is expressed in the placenta,
central nervous system, and fetal liver, and its expression is stimulatedthe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Fig. 1. Characterization of D3 activity in MIN6 cells. Deiodinating activity was mea-
sured in MIN6 cell sonicates. Cell sonicates were incubated for 1 h with various T3
concentrations in the presence of 10 mM DTT. Using the double reciprocal plot of T3
deiodination, the kinetic constants for T3 were calculated as Km = 3.5 nmol/L and
Vmax = 115 fmoles T2 produced/mg protein/h.
23S. Akiyama et al. / Life Sciences 115 (2014) 22–28by a cAMP-mediated pathway (Lamirand et al., 2008). It is noteworthy
that D3-mediated thyroid hormone inactivation promotes insulin
secretion from pancreatic β cells (Medina et al., 2011).
GLP-1 is produced in pancreatic α-cells and enteroendocrine L-cells
fromproglucagon,which is encoded by a glucagon gene, and is critical to
glucose homeostasis (Stoffers et al., 2000; Baggio and Drucker, 2007).
Intestinal endocrine cells secrete GLP-1 when nutrients such as car-
bohydrates, lipids, and proteins are digested. GLP-1 affects β-cells by
amplifying glucose-induced insulin secretion, promoting prolifera-
tion, and inhibiting apoptosis (Li et al., 2003; Baggio and Drucker,
2007). GLP-1 increases intracellular cAMP in β-cells via the GLP-1 re-
ceptor and G-protein coupling pathway that activates PKA-dependent
and -independent pathways (e.g., cAMP-guanine nucleotide exchange
factor pathway) (Kwon et al., 2004). GLP-1 also inhibitsα cell postpran-
dial glucagon secretion (Brubaker and Drucker, 2004; Baggio and
Drucker, 2007).
Whether GLP-1 regulates iodothyronine deiodinase activity remains
unknown, although GLP-1 increases intracellular cAMPwhichmay reg-
ulate iodothyronine deiodinase expression in pancreatic β-cells. Here
we identiﬁed D3 expression in mouse insulinoma cell line-derived
cultured MIN6 cells and examined the mechanisms underlying GLP-1-
mediated D3 expression.
Materials and methods
Materials
[125I]T3 and [125I]rT3 were purchased fromNEN Life Science Products
Corp. (Boston, MA). LH-20, ECL reagent, and HYPERﬁlm-ECL were from
GE Healthcare Bio-Sciences Corp. (Piscataway, NJ). AG 50W-X2 resin
and protein assay kits were from Bio-Rad Laboratories, Inc. (Hercules,
CA). Glucagon-like peptide-1 (7-36)-amide (GLP-1) was obtained
from the Peptide Institute (Osaka, Japan). All other chemicals at the
highest quality were obtained from Sigma-Aldrich Corp. (St. Louis,
MO) or Wako Pure Chemical Industries, Ltd. (Osaka, Japan) unless oth-
erwise indicated.
Cell culture
MIN6 cells were kindly provided by Dr. Masahiro Hosaka and Dr.
Toshiyuki Takeuchi (Institute for Molecular and Cellular Regulation,
GunmaUniversity, Maebashi, Japan).MIN6 cells were cultured as previ-
ously described (Miyazaki et al., 1990). Brieﬂy, MIN6 cells (passages
18–25) were cultured in DMEM (containing 15% heat-inactivated fetal
bovine serum, 7 μL/L 2-mercaptoethanol) in culture ﬂasks under a
humidiﬁed atmosphere of 95% air and 5% CO2 at 37 °C, and the culture
medium was changed every 3 days. The MIN6 cells were passaged
once weekly following detachment using 0.25% trypsin-ethylenediamine
tetra-acetate (EDTA) solutionwhen the cells reached 80%–90% conﬂuence.
All experiments using pseudo-islets were conducted 6–8 days after
subculturing MIN6 cells. To quantify iodothyronine deiodinase activity
and its mRNA expression, MIN6 cells were cultured in 6-well plates.
When the cells reached conﬂuence, the medium was replaced with
DMEM supplemented with 10% thyroid hormone-stripped fetal bovine
serum (Samuels et al., 1979) for 24 h. The cells were then incubated in
the thyroid hormone-depleted medium containing compounds to be
tested for the indicated hours.
Measurement of D3 and D1 activities
For the measurement of D3 activity, MIN6 cells in each well were
washed twice with PBS, scraped off the plate, and transferred into
1-mL ice-cold assay buffer [100mMpotassiumphosphate (pH 7.0) con-
taining 1 mM EDTA and 10 mM dithiothreitol (DTT)]. After centrifu-
gation at 3000 rpm for 10min at 4 °C, the resultant precipitates were
sonicated in assay buffer and incubated in a total volume of 50 μLwith [125I]T3, which was puriﬁed using LH-20 column chromatography
on the day of the experiment, and in the presence or absence of 1mM6-
propyl-2-thiouracil (PTU) or 1 mM iopanoic acid (IOP) with several
concentrations of unlabeled T3. The reaction products were analyzed
using HPLC (Hitachi Co., Tokyo, Japan). The incubation mixtures were
extracted with 2 volumes of absolute ethanol, evaporated, dissolved in
acetonitrile/water (32:68), applied to the C18 column (Shimazu Co.,
Kyoto, Japan), and eluted with acetonitrile/water/phosphoric acid
(32:68:0.1). The ﬂow rate was 1 mL/min, and each 0.5-min fraction
was collected and counted for radioactivity. The protein
concentration was determined by Bradford's method using BSA as a
standard. The deiodinating activity was calculated as femtomoles of
T2 produced/mg protein/h from T3 (Bessho et al., 2010).
D1 activity was measured as previously described (Miyashita et al.,
1995). MIN6 cells were sonicated in ice-cold assay buffer [100 mM
potassium phosphate (pH 7.0) containing 1 mM EDTA and 0.5 mM
DTT], and incubated in a total volume of 50 μL with 0.5 μM [125I] rT3
for 5 min at 37 °C. The reaction was terminated by the addition of
100 μL 2% BSA and 800 μL 10% trichloroacetic acid. After centrifugation
at 3000 rpm for 10min at 4 °C, the supernatant was applied to a column
packedwith AG 50W-X2 resin (bed volume, 1mL) and then elutedwith
2 mL 10% glacial acetic acid. Separated 125I was counted with a γ-
counter. Nonenzymatic deiodination was corrected by subtracting 125I
released in control tubes without cell sonicates. The deiodinating
activity was calculated as picomoles of I− released/mg protein/min,
after multiplication by a factor of two to correct random labeling at the
equivalent 3′ and 5′ positions.
Reverse transcription and real-time polymerase chain reaction (PCR)
We performed quantitative real-time PCR to examine D3 and D1
mRNA expression in MIN6 cells (Bessho et al., 2010; Ogiwara et al.,
2013). Total RNA was isolated from MIN6 cells using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
After treatment with deoxyribonuclease I (Invitrogen) to remove con-
taminatingDNA, cDNAwas synthesizedwith TaqMan reverse transcrip-
tion reagent (Applied Biosystems, Foster City, CA) using 1-μg RNA as a
template and random hexamers as primers in a total reaction volume
of 20 μL. Subsequently, 5 μL of the cDNA was ampliﬁed in a TaqMan
7500 real-time PCR apparatus using mouse D3 (Dio3 mRNA probe
Mm00548953_s1), mouse D1 (Dio1 mRNA probe Mm00839358_m1),
and mouse G3PDH (GAPDH probe Mm99999915_g1) TaqMan gene
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Fig. 2. Effects of forskolin on D3 mRNA and D3 activity in MIN6 cells. MIN6 cells were
incubated with forskolin (10−5 M) for 3 h to perform a real-time PCR analysis of D3
mRNA and 6 h to measure D3 activity. D3 mRNA and D3 activity are represented by the
mean ± SE of 3 wells. *p b 0.05 (compared with control).
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Fig. 3. Effect of GLP-1 on D3mRNA andD3 activity inMIN6 cells. a)MIN6 cells were incubated fo
wells. *p b 0.05 (compared with control). b) MIN6 cells were incubated for 3 h with various c
(compared with control). c) MIN6 cells were incubated for a varying number of hours wit
*p b 0.05 (compared with control). d) MIN6 cells were incubated for a varying number of hou
(compared with control).
24 S. Akiyama et al. / Life Sciences 115 (2014) 22–28expression assays (Applied Biosystems) (Wang et al., 2010). Messenger
RNA levels were expressed as arbitrary units after correcting for mouse
G3PDH.
Measurement of cAMP accumulation
Cyclic AMP accumulation in the MIN6 cells was quantiﬁed using
previously described methods (Al-Majed et al., 2004). MIN6 cells
were plated into 6-well plates with a ﬁnal density of approximately
5 × 105/well and incubated with DMEM containing forskolin, GLP-1
or exendin-4. After incubating for 15 min at 37 °C, the medium was
removed and stored at−20 °C until the cAMP assay. Cyclic AMP con-
centration was measured by a cAMP RIA kit (Yamasa Co., Choshi,
Japan) (Murakami et al., 1995).
Measurement of insulin concentration
MIN6 cells were plated into 12-well plates with a ﬁnal density of
approximately 5 × 105/well. Before the experiments, MIN6 cells were
preincubated in the presence or absence of T3 for 30 min at 37 °C in
0.1% BSA added glucose-free Krebs–Ringer bicarbonate HEPES buffer
(KRBH):129 mM NaCl, 4.8 mM KCl, 5.0 mM NaHCO3, 1.2 mM
KH2PO4,1.2 mM MgSO4, 1.26 mM CaCl2, 5.0 mM glucose, and 10 mM
HEPES, pH 7.4. MIN6 cells were then incubated with 25 mM glucose
containing GLP-1 and/or T3 for 15 min. Insulin concentration in the*
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Fig. 4. Characterization of D3 activity inMIN6 cells stimulated by GLP-1. MIN6 cells were in-
cubated for 3 hwith DMEMcontainingGLP-1 (10−8M). Deiodinating activitywasmeasured
in the cell sonicates using several concentrations of T3. Using the double reciprocal plot, the
kinetic constants for T3, control, and 10−8 M GLP-1 treatment in MIN6 cells were calculated
as Km= 2.1 nmol/L and 1.83 nmol/L and Vmax = 192 fmoles T2 produced/mg protein/h
and 435 fmoles T2 produced/mg protein/h, respectively.
25S. Akiyama et al. / Life Sciences 115 (2014) 22–28incubation buffer was measured using an insulin RIA kit (Eiken Chemi-
cal, Tokyo, Japan) (Nakagawa et al., 2009).
Statistical analysis
All values are expressed as means± standard errors (SEs). Statis-
tical differences between groups were evaluated by ANOVA or
Student's t-test.
Results
Characteristics of D3 activity in MIN6 cells
After incubating MIN6 cell sonicate with [125I]T3 in the presence of
10 mM DTT, HPLC analysis revealed only 2 clear peaks that corre-
sponded to T3 and T2. Monodeiodination of T3 was dependent on the
protein concentration and incubation period for up to 2 h. Incuba-
tion at 0 °C or preheating the cell sonicate at 56 °C for 30 min
completely abolished the deiodination. The deiodinating activity was
not inﬂuenced by 1 mM PTU, but it was completely inhibited by 1 mM
IOP. Using a double reciprocal plot with several T3 concentrations, we
calculated the T3 kinetic constants and found that Km was equal toGLP-1 Exendin-4
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Fig. 5. Effects of GLP-1 and exendin-4 on D3 mRNA, D3 activity, and cAMP production in MIN6
D3mRNAandD3activity are representedby themean±SEof 3wells. *pb 0.05 (comparedwith co
cAMP accumulation in the incubation medium was measured using RIA. *p b 0.05 (compared3.5 nmol/L and that the maximum velocity (Vmax) was equal to
115 fmoles T2 produced/mg protein/h (Fig. 1). These results indicate
that T3 deiodinating activity is present in MIN6 cells and that the
characteristics of this activity are compatible with those of D3.D3 mRNA expression and the effects of forskolin on D3 expression in MIN6
cells
Real-time PCR demonstrated D3 mRNA expression in MIN6 cells. As
shown in Fig. 2, 3-h and 6-h incubation with 10−5 M forskolin markedly
increased D3mRNA and D3 activity, respectively, inMIN6 cells. Forskolin
stimulation increased Vmax, with no effect on the Km of T3 deiodinating
activity (data not shown). In addition, intracellular cAMP accumulation
in MIN6 cells increased with 10−5 M forskolin treatment (data not
shown). These results indicate that a cAMP-mediated pathway regu-
lates D3 expression in MIN6 cells.Effects of GLP-1 on D3 mRNA and D3 activity in MIN6 cells
Because GLP-1 increases intracellular cAMP through the GLP-1 re-
ceptor and G-protein coupling pathway in MIN6 cells (Yamato et al.,
1997), we examined whether GLP-1 affected D3 mRNA and D3 activity
in MIN6 cells. We observed that D3 mRNA and D3 activity in MIN6
cells increased with GLP-1 in a dose-dependent manner (Fig. 3a,b).
D3 mRNA and D3 activity increased by 10−8 M GLP-1 and reached
peak levels at 3 h (Fig. 3c) and 6 h (Fig. 3d), respectively, in MIN6 cells.
Using the double reciprocal plot with various T3 concentrations,
we calculated the T3 kinetic constants for control and 10−8 M GLP-1
treatments. These calculations were as follows: Km = 2.1 nmol/L and
1.83 nmol/L and Vmax = 192 fmoles T2 produced/mg protein/h and
435 fmoles T2 produced/mg protein/h, respectively, in MIN6 cells
(Fig. 4).GLP-1 and exendin-4 affected D3 mRNA, D3 activity, and cAMP production
in MIN6 cells
We examinedwhether the GLP-1 receptor agonist exendin-4, which
is widely used to treat patients with diabetes (Wei et al., 2012), affected
D3 expression in MIN6 cells. As indicated in Fig. 5a, both GLP-1 and
exendin-4 signiﬁcantly stimulated D3 mRNA and D3 activity in MIN6
cells.
Cyclic AMP accumulation increased signiﬁcantly after 15 min of
incubation with 10−8 M GLP-1 and 10−8 M exendin-4 in MIN6 cells
(Fig. 5b). These results indicate that GLP-1 and exendin-4 stimulate
D3 expression in MIN6 cells via a cAMP-mediated pathway.b
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26 S. Akiyama et al. / Life Sciences 115 (2014) 22–28Protein kinase A inhibitor affected GLP-1-stimulated D3 mRNA and D3
activity in MIN6 cells
To determine the extent towhich the cAMP-PKA-mediated pathway
regulated D3 expression in MIN6 cells, we examined whether the PKA
inhibitor H-89 affected GLP-1 stimulated D3 mRNA and D3 activity
in MIN6 cells. The increase in D3 mRNA and D3 activity that followed
3-h incubation with 10−8 M GLP-1 in MIN6 cells decreased in the
presence of 10−5 M H-89 (Fig. 6a, b). These results suggest that D3
expression is pretranslationally regulated by GLP-1 through a GLP-1
receptor-cAMP-PKA-mediated pathway.
Effects of GLP-1 on D1mRNA and D1 activity in MIN6 cells
Because D1 mRNA and D1 activity were detected in MIN6 cells, we
examined the effects of GLP-1 on D1 expression in MIN6 cells. In con-
trast to D3 expression, incubation with 10−8 M GLP-1 did not affect
D1 mRNA and D1 activity in MIN6 cells (Fig. 7).
Effect of T3 on GLP-1 stimulated insulin secretion in MIN6 cells
In order to investigate the physiological role of thyroid hormones
in the regulation of insulin secretion, we studied the effect of T3 on
the GLP-1 stimulated insulin secretion in MIN6 cells (Fig. 8). TheD
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Fig. 7. Effects of GLP-1 on D1 mRNA and D1 activity in MIN6 cells. MIN6 cells were incu-
bated with GLP-1 (10−8 M) for 3 h to perform a real-time PCR analysis of D1 mRNA and
measure D1 activity. D1 mRNA and D1 activity are represented by the mean ± SE of
3 wells and 3 dishes, respectively. *p b 0.05 (compared with control).addition of 10−7 M T3 to the incubation medium signiﬁcantly sup-
pressed 10−8 M GLP-1 stimulated insulin secretion.
Discussion
Using HPLC analysis, we demonstrated that T3 deiodinating activity
was present in a mouse insulinoma cell line, MIN6 cells. T3 deiodinating
activity had a low Km for T3 and was not affected by 1 mM PTU. There-
fore, the characteristics of T3 deiodinating activity in MIN6 cells are
compatible with those of D3 (Bianco et al., 2002; Bessho et al., 2010).
We also identiﬁed D3 mRNA in MIN6 cells, which conﬁrmed D3 ex-
pression in these cells. Forskolin signiﬁcantly increased D3 mRNA
and D3 activity, thus implicating a cAMP pathway in mediating the
pretranslational regulation of D3 expression in MIN6 cells.
The physiological roles of thyroid hormones in glucose homeostasis
and pancreatic β-cell function remain unclear. Hypothyroidism induces
fasting hyperglycemia and decreases plasma insulin levels in mice
following glucose stimulation (Taguchi et al., 2010). T3 improves rat
pancreatic islet function and survival (Verga Falzacappa et al., 2010),
and thyroid hormone promotes postnatal rat pancreatic β-cell develop-
ment and glucose-responsive insulin secretion (Aguayo-Mazzucato
et al., 2013). Plasma free T3 concentrations are positively associated
with insulin secretion in euthyroid individuals (Ortega et al., 2008). In
addition, T3 is a protective factor against STZ-induced diabetes (Verga
Falzacappa et al., 2011), and thyroid hormone receptor α-1 expression
occurs in pancreatic islets (Zinke et al., 2003). In contrast, systemic hy-
perthyroidism can decrease glucose tolerance and the insulin secretory
capacity of β-cells (Lenzen et al., 1975; Ximenes et al., 2007). In rats, T4
can induce apoptosis in pancreatic β-cells (Jörns et al., 2002). Recently,
D3 expression has been identiﬁed in mouse perinatal pancreatic β-cells
and human adult pancreatic β-cells, and D3-mediated thyroid hormone
inactivation is thought to participate in glucose-stimulated insulin
secretion from β cells (Medina et al., 2011).
The MIN6 cell line is one of a few pancreatic β-cell lines that retain
the insulin-secretory response to glucose and other secretagogues
(Miyazaki et al., 1990; Ishihara et al., 1993), and its characteristics are
similar to those of islets isolated from mice. Therefore, MIN6 cells
are considered particularly useful for analyzing the molecular mecha-
nisms of glucose-stimulated insulin secretion in pancreatic β-cells. The
present results indicating D3 expression in MIN6 cells are consistent
with those for D3 expression in mouse and human pancreatic β-cells
(Medina et al., 2011). Together, these results indicate that the MIN6
cell line is a useful model for studying D3 expression in pancreatic
β-cells and D3 contributions to β-cell function.
Forskolin-mediated D3 expression in MIN6 cells is consistent with
previous observations that D3 expression is regulated through a cAMP-
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Fig. 8. Effects of T3 on GLP-1 stimulated insulin secretion in MIN6 cells. MIN6 cells were
incubated for 15 min with GLP-1 (10−8 M) in the presence or absence of T3 (10−7 M).
Insulin concentration is represented by the mean ± SE of 3 wells. *p b 0.05 (compared
with control).
27S. Akiyama et al. / Life Sciences 115 (2014) 22–28mediated pathway inmany cells and tissues at the pretranslational level.
Furthermore, this phenomenon is consistent with the existence of a
cAMP response element in the promoter region of the D3 gene
(Lamirand et al., 2008).
In the present study, GLP-1 rapidly stimulated D3 mRNA and D3
activity in dose-dependent manners, although GLP-1 did not affect D1
expression in MIN6 cells. The GLP-1-mediated increases in D3 mRNA
and D3 activity were abolished by the PKA inhibitor H-89,
implicating pretranslational regulation of D3 expression in MIN6Ca2+
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Fig. 9. Regulation and proposed physiological roles of D3 in MIN6 cells. D3 expression is stimu
β-cells. D3 activity is involved in thyroid hormone inactivation, which may enhance insulin secells through a GLP-1 receptor-cAMP-PKA-mediated mechanism. Fur-
thermore, exendin-4, a speciﬁc GLP-1 receptor agonist, stimulated D3
mRNA and D3 activity in MIN6 cells.
The GLP-1 receptor is widely distributed in the pancreatic islets, hy-
pothalamus, brainstem, lung, heart, kidney, and gastrointestinal tract
(Holst, 2007). GLP-1 and its analog have been extensively studied
because of the physiological potentiation of glucose-induced insulin se-
cretion (Holst, 2007). It is noteworthy that GLP-1 treatment can inhibit
the apoptosis of human islets (Farilla et al., 2003). GLP-1 is released
from gut endocrine cells during nutrient digestion, but it is rapidly
degraded by dipeptidyl peptidase-4 (DPP4). GLP-1 stimulates glucose-
dependent insulin secretion through the GLP-1 receptor, which is
expressed in the membranes of pancreatic islet cells (Moens et al.,
1996). The GLP-1 receptor is coupled to adenylate cyclase through a
Gsα subunit, which increases cAMP concentration that subsequently
activates a PKA-mediated pathway (Nakazaki et al., 2002). GLP-1 poten-
tiates glucose-induced insulin secretion through cAMP/PKA signaling,
and this leads to phosphorylation of regulatory proteins associated
with secretion in pancreatic β-cells. GLP-1 receptor agonists and DPP4
inhibitors are widely used in clinical settings to treat diabetes. The
present results indicate that D3 expression in MIN6 cells is regulated
through a GLP-1 receptor-cAMP-PKA-mediated mechanism. Further-
more, exendin-4, a speciﬁc GLP-1 receptor agonist, pretranslationally
stimulated D3 expression in MIN6 cells. These results suggest that
D3 may inactivate T4 and T3 when stimulated by GLP-1 as well as the
pharmacological effect of GLP-1 receptor agonists and DPP4 inhibitors.
In the present study, T3 suppressed GLP-1 stimulated insulin secre-
tion inMIN6 cells. These results suggest that the suppression of intracel-
lular T3 concentration by D3 may be involved in the stimulation of
insulin secretion by GLP-1. These results support the concept that
suppression of thyroid hormone signaling by D3 may be a novel target
for therapeutic intervention in diabetes (Medina et al., 2011).
D3 expression inMIN6 cells, which is stimulated by GLP-1 through a
GLP-1 receptor-cAMP-PKA-medicated mechanism, suggests that GLP-1
may modulate insulin secretion via T4 -to-rT3 and T3-to-T2 conversion
by D3 expressed in pancreatic β-cells (Fig. 9). Because apoptosis ofInsulin
secretion
Thyroid hormone
inactivation
ylate Cyclase
tein Kinase A 
P-1    
tor
lated by GLP-1 through a GLP-1 receptor-cAMP-PKA-medicated mechanism in pancreatic
cretion.
28 S. Akiyama et al. / Life Sciences 115 (2014) 22–28β-cells is induced by T4 (Jörns et al., 2002), inactivation of thyroid
hormones by D3 may participate in GLP-1-mediated inhibition of
apoptosis in pancreatic β-cells.
Conclusions
In summary, the present study demonstrates that D3 is expressed
in MIN6 cells, which is regulated by GLP-1 through a GLP-1 receptor-
cAMP-PKA-mediated pathway. The regulation of intracellular T3
concentration by D3 may be involved in the stimulation of insulin
secretion by GLP-1.
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